Question-and-Answer Session
Operator
(Operator Instructions). We'll have our first question from Ken Worthington with JPMorgan.
Kenneth Worthington - JPMorgan
First, can you talk about, like, are there structural advantages for those that clear CDS in the US with ICE, to also clear CDS with ICE in Europe and vice versa? Like I don't think there's cross margining opportunities, but are there other reasons that customers who clear in the US will also clear in Europe?
Jeffrey Sprecher
Ken this is Jeff. Thanks for the question. There is, I guess would you call structural standpoint in that we're using essentially the same connectivity, the same risk models and technology in both places. So we make it easy for a global market participant to trade however they normally trade, wherever they normally trade, put that trade essentially on our network, and we will route it then to the appropriate venue.
We have previewed for the regulators a view of global clearing of linking clearing houses, which is something that is important to us, and it's partly at the root of our owning clearing houses in various locations around the world. But, moving the actual moneys globally and offsetting risk globally is complicated simply because of differing bankruptcy regimes.
So, one has to move quite thoughtfully and put in place a system of checks and balances and fire walls, so that you can prevent contagious risk. So we're having that dialogue with regulators. We've actually been having that dialogue for a few years. I think over time it will evolve into a model where we are better able to manage risk globally.
Jeffrey Sprecher
Then as a follow-up, you created buy-side clearings for ICE Trust in the US. Are you doing the same thing or is the same thing possible buy-side also in the UK?
Scott Hill
Actually, Ken, the solution that we've worked on, we believe can apply and will apply in the US and in Europe.
Jeffrey Sprecher
There is some subtle differences between the two, but we believe it largely applies to both.
Operator
We will go next to Daniel Harris with Goldman Sachs.
Daniel Harris - Goldman Sachs
Jeff or Scott, I think you mentioned that the new products in your OTC capability set you launched about 100 I think thus far in the year with about $1.5 in revenues. Where are you seeing most of the uptick thus far? To some extent, when you think about the next six to 12 months, where do you see the opportunities from new products that you are not currently in today?
- To read the full transcript on Seeking Alpha, click here »
